News and Updates

The AI-designed drug Rentosertib enters Phase III trials for idiopathic pulmonary fibrosis. Explore how this breakthrough impacts the future of lung disease.

New industry standards for AI validation are transforming clinical trials. Discover how algorithmic rigor is redefining the future of drug development.

Teitur Trophics reports successful Phase I results for TT-P34, a first-in-class peptide therapy showing promise for treating Parkinson's disease.

Tyra Biosciences selects the 60mg dose of dabogratinib for its Phase 2 NMIBC trial, targeting a new bladder-sparing therapy for BCG-unresponsive patients.

Seismic Pharmaceuticals has launched a Phase 3 trial for Istaroxime, a novel therapy targeting cardiogenic shock. Learn about this breakthrough heart trial.

Insilico Medicine has launched a Phase III trial for Rentosertib, an AI-discovered drug targeting Idiopathic Pulmonary Fibrosis. See the latest progress here.

The FDA has granted Priority Review to Roche’s Enspryng for MOGAD. Learn about the trial data and the potential impact on treating this rare neuro-disorder.

Discover how modern clinical trials are shifting toward patient-centric models to improve recruitment, retention, and the success of new drug development.

India has approved QDENGA, the country's first dengue vaccine. Learn how this tetravalent shot provides protection against all four virus serotypes.

Discover how AI is transforming clinical trials through predictive modeling, automated patient recruitment, and enhanced data accuracy for faster results.